Lmr Partners LLP Cassava Sciences Inc Call Options Transaction History

Lmr Partners LLP

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 07, 2024	SELL	$9.57 - $35.08 $440,220 - $1.61 Million	-46,000 Reduced 8.59%	489,800 $14.4 Million
Q2 2024 Aug 14, 2024	BUY	$12.35 - $26.11 $495,235 - $1.05 Million	40,100 Added 8.09%	535,800 $6.62 Million
Q1 2024 May 15, 2024	SELL	$18.44 - $26.41 $597,456 - $855,684	-32,400 Reduced 6.14%	495,700 $10.1 Million
Q4 2023 Feb 14, 2024	BUY	$12.64 - $30.11 $905,024 - $2.16 Million	71,600 Added 15.68%	528,100 $11.9 Million
Q3 2023 Nov 14, 2023	BUY	$16.64 - $25.32 $1.7 Million - $2.59 Million	102,400 Added 28.92%	456,500 $7.6 Million
Q2 2023 Aug 14, 2023	BUY	$21.59 - $27.88 $7.65 Million - $9.87 Million	354,100 New	354,100 $8.68 Million

207

14M

2.98M

6.57M

Ticker SAVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,097,900
Market Cap $160M
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.